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Abstract. In this study, nanosuspension of stable iodine (127I) was prepared by nanoprecipitation process
in microfluidic devices. Then, size of particles was optimized using artificial neural networks (ANNs)
modeling. The size of prepared particles was evaluated by dynamic light scattering. The response surfaces
obtained from ANNs model illustrated the determining effect of input variables (solvent and antisolvent
flow rate, surfactant concentration, and solvent temperature) on the output variable (nanoparticle size).
Comparing the 3D graphs revealed that solvent and antisolvent flow rate had reverse relation with size of
nanoparticles. Also, those graphs indicated that the solvent temperature at low values had an indirect
relation with size of stable iodine (127I) nanoparticles, while at the high values, a direct relation was
observed. In addition, it was found that the effect of surfactant concentration on particle size in the
nanosuspension of stable iodine (127I) was depended on the solvent temperature.
KEY WORDS: ANNs; microfluidic; nanoprecipitation; particle size; stable iodine.
INTRODUCTION
Nanosuspension formulation of stable iodine (127I) can
have a remarkable advantageous over the usual form of io-
dine. Stable iodine (127I) is one of the main preventive mea-
sures used for those people near a nuclear event to lessen
absorption of released radioiodine in their thyroid glands.
Since, in such cases, there is a competition between stable
iodine (127I) and radioiodine to be absorbed in the thyroid;
therefore, nanosuspension form of the stable iodine (127I) may
increase uptake rate of stable iodine (127I) in comparison to
radio iodine, reducing uptake of radio iodine. Various
nanosizing techniques have been developed to increase
dissolution velocity and solubility of drug through enhancing
surface area to volume ratio of the drug particles, e.g.,
nanosuspension engineering. During the formulation of
nanosuspensions, drug particles under 1 μm are distributed
in an outer liquid phase and are fixed by stabilizers (1,2). The
nanosuspension engineering is a simple procedure which is
generically applicable for most of drug molecules (3). Also,
in comparison of the conventional formulation systems, it is
shown that formulation of nanosuspension is associated with
advantages such as increased absorption rate, enhanced dis-
solution, improved bioavailability (4,5), increased adhesion,
high drug loading (6,7), and scale-up capability (8).
Typically, during nanosuspensions process, drug
nanocrystals are made in a liquid medium using top-down
(i.e., milling by media and high pressure homogenizer) or
bottom-up (i.e., precipitation) methods. In the precipitation
process, a drug is solved in a solvent to produce the supersat-
urated solution, then mixed with an antisolvent in order for
precipitation of drug molecules and form drug nuclei
(nucleation) (9). In microfluidic devices technology, the nu-
cleation procedure is performed in microreactors with internal
diameters usually smaller than 1 mm (10). The major advan-
tages of microfluidic channel are high surface area to volume
ratio and low Reynolds number which refers to laminar flow
patterns (i.e., a liquid flows in parallel layers) (11,12).
Therefore, a significant reduction in reagents usage, time of
experiments, and costs is observed while reproducible exper-
iments and performance are provided (9,13,14). Furthermore,
monodispersed particles are commonly obtained in this meth-
od. In the microfluidic nanoprecipitation, at first, a
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supersaturated solution of drug is prepared by dissolving the
drug in a solvent. The solution obtained is then injected into
an antisolvent, as a poor solvent, to form and grow of nucle-
ation sites on the fluids interface (see Fig. 1). Using surfactant
to limit drug crystal growth, it is possible to prevent creation of
microparticles.
Effects of changing the various parameters of the
microfluidic precipitation process, including flow rate of
drug solution and antisolvent, drug saturation level, chan-
nels internal diameter, microreactor inlet angle, drug con-
centration, precipitation temperature, and surfactant
concentration, on the size of nanosized drug particles have
been evaluated widely in previous studies (15–20). It is
observed that increasing in the flow rate of antisolvent
and decreasing in the flow rate of drug solution, sharpen
inlet angles and lessen saturation levels resulted in smaller
particle sizes (19). In another study, it was shown that
design of microreactor and processing conditions may
have an influence on the hydrocortisone particle size dur-
ing nanoprecipitation using microfluidic reactors (18).
Also, microfluidic nanoprecipitation of the other pharma-
ceutical ingredients such as danazol (20), norfloxacin (15),
cefuroxime axetil (16), and rifampicin (17) have shown
the creation of drug particles with controlled sizes, im-
proved dissolution rate, continuous synthesis, and amor-
phous profile.
In this study, we used artificial neural networks
(ANNs) to find a predictive and quality model describing
the effects of experiment parameters (independent vari-
ables) on the particle size (dependent variable) of the
stable iodine (127I) nanosuspension formulation obtained
by nanoprecipitation in microfluidic reactors. ANNs are
artificial intelligence tools which arbitrary find the nonlin-
ear and complex relation between the experimental data
(21). It can be used to predict the relations between
independent variables (i.e., inputs) and corresponding de-
pendent variable(s) (i.e., output(s)) (19), especially in case
of complex experimental data in nanotechnology studies
(22).
MATERIALS AND METHODS
Materials
For the present study, potassium iodide (KI) (Merck
chemicals, Germany), Tween 80 (polysorbate 80) (Sigma-
Aldrich, USA), and absolute ethyl alcohol (ethanol) 99/6%
(V/V) (Jahan Alkol Teb Arak co. (JATA), Iran) were used as
preliminary materials to set experiment up.
Stable Iodine (127I) Nanoprecipitation in Microchannel
Reactor
In order to prepare nanosuspension of stable iodine
(127I) using microfluidic devices, supersaturated solutions
of stable iodine (127I) in distilled water (as solvent) at
given temperatures (24–80°C) were pumped to the
microreactor. Certain flow rates of solvent (0.5–2.4 ml/
min) and antisolvent (0.5–2.5 ml/min) were controlled
using pumps (Fanavaran Nano-Meghyas, Iran). Also, eth-
anol as antisolvent system was mixed with predetermined
concentrations of surfactant (Tween 80) at the controlled
lab temperature of 24±2°C. Temperature of solvent solu-
tion was predetermined and controlled by heater through-
out the study. Microfluidic instrument was fabricated from
the Aluminum material, with internal diameter of 1 mm
and inlet angle of 50°. In order to prevent particles
growth in prepared nanosuspension, the particle size was
measured freshly using dynamic l ight scattering.
Experimentally, 45 samples at random values from four
independent variables (i.e., input factors) including solvent
flow rate (ml/min), solvent temperature (°C), antisolvent
flow rate (ml/min), and surfactant concentration (mg/5 ml)
were prepared, and size of samples was considered as
dependent variable (i.e., output). Obtained data from ex-
perimental study were used to achieve a model by ANNs
modeling to understand effects of four input factors on
the particle size of prepared nanosuspension through
nanoprecipitation in microchannel reactor.
ANNs Modeling
Modeling of the relations between four input factors and
one output parameter was studied using commercially avail-
able ANNs software (INForm v4.02, Intelligensys, UK). Then,
the response surfaces, illustrated as 3D-graphs, were applied
to evaluate the effect of two input parameters on the output
parameter while two other input parameters were fixed at
given values (i.e., low, medium, and high values).
The results of experimental samples were used to train a
model by ANNs. Number of 32 data sets was defined as
training data for teaching the network of relations between
input variables and output variable. Also, three data set (10%
of the training data) were taken as the test data in order to
prevent overtraining during the training process. Details of
the training parameters (listed in Table I) during the modeling
by ANNs have been described previously (23). Following the
training of network, ten more data set (as validation data set
or unseen data) was also used to evaluate the predictive
capability of the model provided by ANNs software. The
predictive capability of the obtained model was finally
Fig. 1. Schematic of nanoprecipitation in microfluidic channels (with
the 1 mm internal diameter)
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validated using correlation coefficient (R2) close to one (24)
calculated for unseen data set (see Table II).
Particle Size Measurement
Relying on the impact of input parameters on the output
parameter predicted by obtained model, an optimum formu-
lation (i.e., nanosuspension of stable iodine (127I) with mini-
mum size) was prepared and evaluated to determine particle
size and morphology.
DLS Analysis
Particle size (statistical mean value of particle diame-
ter) in optimum formulation was measured by dynamic
light scattering (Nano ZS, Malvern instruments, UK) with
PCS software (version 1.27). All samples were analyzed at
lab temperature (controlled at 22°C), freshly diluted by
adding 2 ml deionized water to 1 ml of sample.
TEM Analysis
Evaluating of the nanoparticle size and its morphology of
stable iodine (127I) in the optimized nanosuspension formula-
tion was implemented using transmission electronic micro-
scope (Zeiss EM 10C, Germany).
The optimized sample was dispersed in deionized water
by ultrasonic for 3 min. Two drops of the nanosuspension
sample were put on the copper grid coated by carbon and
placed in lab temperature for 15 min (drying sample).
Subsequently, the grid was put on a holder to be monitored
using TEM at the voltage of 80 kV.
Determination of Stability
Optimization of the stability of the nanosuspension for-
mulation of stable iodine (127I) demands another study that
was out of the scope of our study. Here, physical stability of
obtained nanosuspension formulation of stable iodine (127I)
with minimum size was investigated, in which time of sedi-
mentation was considered as indicator of physical stability of
nanosuspension. Obtained formulation (i.e., sample with min-
imum particle size) was observed daily, in controlled lab tem-
perature of 24±2°C, in order to determine the time of phase
separation of nanoparticles in nanosuspension.
Determination of Entrapment Efficiency of Stable Iodine
(127I)
The percentage of entrapment efficiency was measured
using spectrophotometric detection at 226 nm. At first,
nanosuspension sample of stable iodine obtained (i.e., sample
with minimum particle size) was centrifuged at speed of
10,000 rpm for 20 min, at temperature of 20°C. Then, superna-
tant was separated and content of the free dissolved stable iodine
(127I) was detected by UV–vis spectrophotometer at 226 nm.
The amount of nanosized stable iodine (127I) was determined by
subtraction of amount of initial stable iodine (127I)minus the free
stable iodine (127I) (25). This amount can be entrapment effi-
ciency (EE %) according to the following equation:
Entrapment efficiency EE%ð Þ
¼ initial drug amount − free drug amount
initial drug amount
 100
RESULTS
After the model was generated by ANNs, R2 values of
0.92, 0.81, and 0.80 were obtained for training, test, and
Table II. The Unseen Data Sets Used by ANNs Software
Solvent flow rate
(ml/min)
Solvent
temperature (°C)
Antisolvent flow
rate (ml/min)
Surfactant concentration
(mg/5 ml)
Observed particle
size (nm)
Predicated particle
size (nm)
1.0 80 1.0 1296 185.4 199.3
1.8 60 0.8 1296 104.0 117.1
2.0 60 1.0 864 109.0 116.7
0.8 60 2.5 1296 105.0 104.9
2.0 40 0.5 1080 169.0 175.1
1.0 70 2.5 1296 102.2 124.7
2.0 60 2.1 1252.8 52.1 60.4
1.8 70 1.8 972 116.0 129.4
1.0 50 1.0 1252.8 125.8 128.4
Table I. The Training Parameters Applied in INForm v4.02
Network structure No. of hidden layers 1
No. of nodes in
hidden layer
4
Backpropagation type Incremental
Backpropagation
parameters
Momentum factor 0.8
Learning rate 0.7
Targets Maximum iterations 1000
MS error 0.0001
Random seed 10,000
Smart stop Minimum iterations 20
Test error weighting 0.1
Iteration overshoot 200
Auto weight On
Smart stop enabled On
Transfer function Output Symmetric sigmoid
Hidden layer Symmetric sigmoid
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unseen data, respectively. Resulted values show a satisfactory
trained model. Subsequently, the generated model was used to
evaluate the effect of above-mentioned input parameters on
the particle size in nanosuspension formulation of stable io-
dine (127I). The first choice to determine the relations of
input variables and output parameter could be the method
of sensitivity analyses. In the current study, an alternative
systematic method reported previously (26) was used to de-
termine relations between the input variables and output. As
described previously (19), in this method, the effect of changes
in two input variables on output parameter (i.e., the particle
size) is shown by response surfaces, whereas the remaining input
variables are fixed on the predetermined low, mid-range, and
high amounts.
Considering the procedure explained above, at first, in
order to study change of particle size of stable iodine (127I)
nanosuspension against solvent and antisolvent flow rate, the
other two input variables were fixed at the low, mid-range, and
high values, namely, 936.0, 1024.0, and 1290.0mg/5ml for Tween
80 concentration and 42, 60, and 78°C for solvent temperature.
Resulted three-dimensional graphs are displayed in Fig. 2.
According to these graphs, the effect of antisolvent flow
rate on nanoparticles size, for every fixed data set, clearly
shows that an increase in antisolvent flow rate has led to
a considerable decrease in the particle size of stable io-
dine (127I) nanosuspension. Also, it is obviously demon-
strated that particles size in the formulation of generated
nanosuspension has decreased when the solvent flow rate
in nanoprecipitation process has increased.
Figure 3 shows the effect of Tween 80 concentration and
solvent flow rate on the particle size of stable iodine (127I)
nanosuspension in creation of 3D graphs, when other two
variables, antisolvent flow rate and solvent temperature, are
fixed at the values of low, mid-range, and high (i.e., 0.9, 1.7,
and 2.3 ml/min for antisolvent flow rate, and 42, 60, and 78°C
for solvent temperature).
It is clear that increasing Tween 80 concentration in the
low and mid-range data set of fixed solvent temperature may
lead to reduction in the size of stable iodine (127I) nanoparti-
cles in nanosuspension. Nevertheless, for the higher values of
fixed solvent temperature, an increase in the nanoparticles
size after rising Tween 80 concentration is obvious. Also, it is
Tween 80 concentration
High (1290.0 mg/5ml) Mid-range (1024.0 mg/5ml) Low (936.0 mg/5ml)
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Fig. 2. 3D plots of the nanosuspensions size predicted by the ANNs model fixed at low, mid-range, and high values of the Tween 80
concentration and solvent temperature
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shown that for each data set of fixed antisolvent flow rate and
solvent temperature, any increase in solvent flow rate may
lead to a considerable reduction in the particle size of obtain-
ed nanosuspension, as mentioned above.
Obtained 3D graphs in Fig. 4 show the effect of changes
in solvent temperature and Tween 80 concentration on the
particles size, when solvent flow rate and antisolvent flow
rate are fixed in the amount of low, mid-range, and high
(0.9, 1.7, and 2.3 ml/min for both data set). Based on
Fig. 4, at low solvent temperature of ~45°C, the particle size
in nanosuspension is minimum, showing an indirect relation
with lower temperatures and direct relation with higher
solvent temperatures. Information on the rows and col-
umns in Fig. 4 show that for both data sets of fixed
antisolvent and solvent flow rate, increasing the concen-
tration of Tween 80 results in small decrease in the nano-
particles size of stable iodine (127I).
With attention to the details in Figs. 5, 6, and 7 that show
the changes of nanoparticles size against Tween 80
concentration and flow rate of antisolvent, solvent tempera-
ture and flow rate of antisolvent, and flow rate of solvent and
solvent temperature, respectively, the following findings which
is indicated above can be obtained:
I. Increasing flow rate of solvent and antisolvent during
the nanoprecipitation process can cause to a consider-
able reduction in the particle size in nanosuspension.
II. The relation between size of iodine nanoparticles and
solvent temperature is direct and indirect for high and
low temperatures, respectively.
III. In the low (or mid-range) and high ranges of the
solvent temperature, respectively, increasing the
Tween 80 concentration results in a decrease and
increase poorly at the size of nanoparticles obtained
during nanoprecipitation.
Also, in this study, polydispersity index (PDI) of
nanosuspension samples was determined in the range of
Antisolvent flow rate
High (2.3 ml/min) Mid-range (1.7 ml/min) Low (0.9 ml/min)
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Fig. 3. 3D plots of nanosuspensions size predicted by the ANNs model fixed at low, mid-range, and high values of the antisolvent flow rate and
solvent temperature
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0.09–0.38, which is normal range obtained in microchannel
devices and so their good potential to generate the
monodispersed colloidal disperses, as reported in the former
works (27,28).
After considering all findings, a new nanosuspension for-
mulation of stable iodine (127I) was created to achieve mini-
mum particle size. The nanosuspension sample was prepared
in solvent flow rate of 2.4 ml/min, antisolvent flow rate of
2.5 ml/min, solvent temperature of 45°C, and Tween 80 con-
centration of 1296 mg/5 ml. Particle size of the generated
sample was determined ~20 nm which was evaluated by
DLS and confirmed using TEM (see Fig. 8).
Physical Stability of Nanosuspension of Stable Iodine (127I)
Sedimentation time of obtained nanosuspension of
stable iodine (127I) with minimum particle size was deter-
mined by visual observation. Visual observation of sedimenta-
tion is one of the methods to estimate stability of prepared
nanosuspension (6,9). As nanosuspension of stable iodine is a
deflocculated nanosuspension and produced a densely packed
sediment, sedimentation can be seen by the visual observation.
Finally, physical stability of obtained sample was determined as
68 days.
Entrapment Efficiency of Stable Iodine (127I)
The entrapment efficiency of nanosuspension formula-
tion of stable iodine (127I) with minimum particle size was
determined to be ~82%. This finding show that almost 82%
of supersaturated solution of potassium iodide (KI) powder
was converted into stable iodine (127I) nanoparticles produced
via nanoprecipitation using microfluidic devices.
DISCUSSION
Up to now, various approaches have been introduced
to produce drug nanoparticles. One of the simple and
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Fig. 4. 3D plots of nanosuspensions size predicted by the ANNs model fixed at low, mid-range, and high values of the solvent flow rate and
antisolvent flow rate
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cost-effective methods to prepare nanoparticles is the use
of microfluidics technology (channels with a micrometer
scale) (29). It is indicated recently that fluids manipula-
tion and fine control of fluid interfaces in these channels
is one of the main benefits of this approach. Controlling
the flow and mixing conditions in the microchannels may
yield a reproducible monodispersed nanosuspension and
provide opportunity to better control of particle size
(27,29).
According to the modeling results of our work, par-
ticle size of obtained nanosuspension decreased by in-
creasing flow rate of antisolvent, which is in agreement
with work of H.S.M. Ali et al. (19). This finding is
because of the decrease of drug solubility, by adding
antisolvent to the solvent (increased mixing), which en-
hances the level of supersaturation and consequently re-
sults in a higher nucleation rate than growth rate.
Subsequently, this process leads to generation of smaller
nanosized particles (20). Also, any increase in the flow
rate of antisolvent can result in diminishing the diffusion
process of drug molecules to antisolvent stream per unit
volume of antisolvent. This phenomena can cause to
fewer solute concentration around growing drug nano-
crystal, leading to formation of smaller nanoparticles
(19,29).
In addition, by increasing flow rate of solvent in
stable iodine (127I) nanoprecipitation, the particle size
of prepared nanosuspension decreased, which this finding
is similar to that of Y.F. Su et al. regarding preparation of
continuous nanoparticle using microfluidic-based emul-
sion (30). In fact, this finding may be due to enhance-
ment in the supersaturation level against increased
mixing, obtained with increase at flow rate of solvent
(18,30). Consequently, increasing nucleation than growth
and reduction of particle size can be seen, as expressed
above.
From the results mentioned above, the particles size in-
creased in nanosuspension against higher and lower values of
solvent temperature, while minimum particle size was ob-
served at low range of solvent temperature near to a certain
Solvent flow rate
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Fig. 5. 3D plots of nanosuspensions size predicted by the ANNs model fixed at low, mid-range, and high values of the solvent flow rate and
solvent temperature
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value (~45°C). It can be argued that the high tempera-
ture of solvent leads to increase drug solubility in sol-
vent and consequently, it will be difficult to achieve
high supersaturation level during nanoprecipitation pro-
cess at microfluidic reactor. As a result, this may cause
to a low nucleation rate and increased particle size at
high temperature values in comparison to low solvent
temperature in which solubility of drug in solvent de-
creases and supersaturation occurs easily (31). Also,
nucleation process is a favorable process energetically
(i.e., by releasing heat). Therefore, number of created
drug nuclei increases at low temperature of solvent (i.e.,
high nucleation rate/low growth rate and decrease at
particle size of output) (32). In addition, with increasing
solvent temperature, diffusion of solute molecules into
antisolvent flow will increase. So, more drug nuclei will
form (i.e., enhanced nucleation than growth) (27) and
consequently, particle size in nanosuspension decreases,
as observed in lower ranges of solvent temperature (an
indirect relation).
The impact of surfactant concentration on particle size is
different in low and high values of solvent temperature. The
findings in Figs. 3 and 5 show that particle size in
nanosuspension decreases against increasing Tween 80 con-
centration in low (or mid-range) values of solvent tempera-
ture, as reported in previous studies by M.E. Matteucci et al.
and Y. Dong et al. (33,34). It is clear that surfactant acts as a
steric barrier against particles growth generated by precipita-
tion; as a result, nucleation rate than growth rate increases
with enhancing surfactant concentration (33,34). On the other
hand, an increase at surfactant concentration in the high
values of solvent temperature results in the increasing
particle size of output. This may be due to an increase
in the diffusion coefficient of surfactant at higher temper-
ature that can result in increasing surfactant molecules
uncontrollably on the surface of particles generated during
Solvent flow rate
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Fig. 6. 3D plots of nanosuspensions size predicted by the ANNs model fixed at low, mid-range, and high values of the solvent flow rate and
Tween 80 concentration
1066 Aghajani et al.
nanoprecipitation at microfluidic channel. Consequently,
this can lead to reduce in the mobility of particles dis-
persed and increase in the observed particle size using
dynamic light scattering.
CONCLUSION
In the current study, modeling by ANNs software has
been applied to create a quality model that illustrated
effects of solvent flow rate and temperature, antisolvent
flow rate, and surfactant concentration on the particle size
in nanosuspension formulation of stable iodine (127I) ob-
tained by nanoprecipitation technique at microfluidic de-
vices. The obtained response surfaces after modeling
showed that input parameters have remarkable impacts
on the size of stable iodine (127I) nanocrystals. Enhancement
of flow rate of solvent and antisolvent caused a decrease in the
size of stable iodine (127I) nanoparticles. The low and high
solvent temperature had an indirect and direct relation, respec-
tively, with particle size of nanosuspension. Also, the size of
nanoparticles decreased against increasing the Tween 80 con-
centration in the low values of solvent temperature, while an
increase in Tween 80 concentration at high values of solvent
temperature resulted in increasing particle size.
Antisolvent flow rate
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Fig. 7. 3D plots of nanosuspensions size predicted by the ANNs model fixed at low, mid-range, and high values of the antisolvent flow rate and
Tween 80 concentration
Fig. 8. Picture of stable iodine nanoparticle (Transmission Electron
Microscope (TEM))
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